A Study of Docetaxel and Ramucirumab Versus Docetaxel and Placebo in the Treatment of Stage IV Non-Small Cell Lung Cancer

Clinical trial NCT01703091 · COMPLETED

Trial details

NCT number: NCT01703091
Sponsor: Eli Lilly and Company
Status: COMPLETED
Phase: Phase 2
Study type: INTERVENTIONAL

Non-small Cell Lung Cancer Metastatic

Start date: 2012-12-01
Primary completion: 2014-12-01
Enrollment: 197

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.